Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 2:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,095 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Volume control Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

NCT02224560
View directory record Official record
Conditions
Epilepsy, Lennox Gastaut Syndrome
Interventions
GWP42003-P, Placebo control
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
2 Years to 55 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
20
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2022 · Synced Oct 30, 2026, 2:31 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Neurobiological Similarities of Tinnitus and PTSD

NCT05981391
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Tinnitus
Interventions
resting-state functional MRI, Clinician Administered PTSD Scale for the DSM-5 (CAPS-5), Tympanometry, Tinnitus Assessment, Otoscopy, Pure tone air and bone-conduction, Speech testing, Loudness Discomfort, Quick Speech in Noise Test, Distortion-Product Otoacoustic Emissions (DPOAE)
Diagnostic Test
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 1 Interventional

Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine

NCT00124124
View directory record Official record
Conditions
Melanoma
Interventions
KLH; Peptides; Dendritic Cells, KLH, peptides plus Montanide
Drug
Lead sponsor
Dr. Nina Bhardwaj
Individual
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2015 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Lung Protective Ventilation in Pulmonary Thromboendarterectomy (PTE) Patients

NCT00747045
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, Acute Lung Injury
Interventions
Ventilation Strategy
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2014 · Synced Oct 30, 2026, 2:31 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Dietary Erythritol on Platelet Reactivity and Vascular Inflammation

NCT05967741
View directory record Official record
Conditions
Platelet Aggregation, Spontaneous, Vascular Thrombosis
Interventions
Erythritol, Aspartame
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults

NCT04661839
View directory record Official record
Conditions
COVID-19
Interventions
COVID-HIGIV, Placebo (saline)
Biological · Other
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Dose-Response Effect Exercise and Depression

NCT06166095
View directory record Official record
Conditions
Depression
Interventions
high-dose, Walking attention control, moderate-dose
Other
Lead sponsor
University of Central Florida
Other
Eligibility
18 Years to 25 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 27, 2025 · Synced Oct 30, 2026, 2:31 AM EDT
Recruiting Not applicable Interventional

Fresh Autologous Whole Blood Transfusion After Cardiopulmonary Bypass

NCT03204357
View directory record Official record
Conditions
Cardiac Disease, Bleeding Postoperative
Interventions
Fresh Autologous whole Blood, Standard of Care Expectant management of bleeding
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 90 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Calcineurin Inhibitor-Free Interventions BMT CTN 1301 for Prevention of Graft-versus-Host Disease (BMT CTN 1301)

NCT02345850
View directory record Official record
Conditions
Acute Leukemia, Myelodysplasia
Interventions
Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate, Mobilized CD34-selected Peripheral Blood Stem Cell graft, Unmanipulated Bone Marrow Graft with Cyclophosphamide, Cyclophosphamide, Tacrolimus, Methotrexate
Procedure · Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 65 Years
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
28
States / cities
Duarte, California • Stanford, California • Gainesville, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK2330672 Administered With Metformin to Type 2 Diabetes Patients

NCT02202161
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK2330672, Placebo, Sitagliptin, Metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 64 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Tetravalent Chimeric Dengue Vaccine Trial

NCT01110551
View directory record Official record
Conditions
Dengue
Interventions
Placebo (SC), Placebo (ID), Modified Live Tetravalent Chimeric Dengue Vaccine (SC), Modified Live Tetravalent Chimeric Dengue Vaccine (ID)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 4, 2013 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes

NCT01720446
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, placebo
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
50 Years and older
Enrollment
3,297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
97
States / cities
Birmingham, Alabama • Chandler, Arizona • Anaheim, California + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 30, 2026, 2:31 AM EDT
Recruiting Not applicable Interventional

Exposure-Based CBT for Avoidant/Restrictive Food Intake in Functional Dyspepsia

NCT05587127
View directory record Official record
Conditions
Avoidant/Restrictive Food Intake Disorder, Dyspepsia, Feeding and Eating Disorders, Cognitive Behavioral Therapy, Appetite Regulation, Functional Dyspepsia, Post-prandial Distress Syndrome, Behavioral Medicine
Interventions
Cognitive Behavioral Therapy
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 30, 2026, 2:31 AM EDT
Not listed Not applicable Interventional

NIH Release/Relock Socket

NCT04305782
View directory record Official record
Conditions
Lower Limb Amputation Below Knee (Injury)
Interventions
Release/Relock Socket - In Lab, Release/Relock Socket - Out of Lab, Release/Relock Socket & Control
Device
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Not applicable Interventional

Trial With Deltex Cardio in Elective Bowel Resection Patients

NCT01244685
View directory record Official record
Conditions
1 Fluid Management
Interventions
Deltex CardioQ Probe
Device
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 3 Interventional

Pilot: Intraoperative TAP Block and Post-operative Pain Control for Minimally Invasive Hysterectomy for Endometrial Cancer

NCT05763667
View directory record Official record
Conditions
Post Operative Pain, Gynecologic Cancer
Interventions
Liposomal bupivacaine, Bupivacain
Drug
Lead sponsor
Tufts Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 24, 2025 · Synced Oct 30, 2026, 2:31 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Paracervical Block for Pain Control With Osmotic Dilator Placement

NCT02354092
View directory record Official record
Conditions
Abortion Late, Pain
Interventions
Local anesthetic for tenaculum placement, Sham, Paracervical Block, Dilator Placement, Post-procedural assessment, Preprocedural pain control
Procedure · Behavioral · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2019 · Synced Oct 30, 2026, 2:31 AM EDT
Recruiting Phase 2 Interventional

Study of Tirzepatide for Recovery and Alcohol Use Management

NCT06727331
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Tirzepatide, Saline Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 30, 2026, 2:31 AM EDT
Withdrawn Phase 2Phase 3 Interventional

Quetiapine Treatment for Pediatric Delirium

NCT03572257
View directory record Official record
Conditions
Delirium
Interventions
Quetiapine, Placebo
Drug · Other
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
Up to 21 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 30, 2026, 2:31 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Development of an Algorithm That Predicts Hypoventilation Due to an Opioid Overdose

NCT03845699
View directory record Official record
Conditions
Drug Overdose, Opioid-Related Disorders
Interventions
Diagnostic algorithms that detects/predicts hypoventilation
Device
Lead sponsor
RTM Vital Signs, LLC
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 9, 2019 · Synced Oct 30, 2026, 2:31 AM EDT
Not yet recruiting Phase 2 Interventional

CSF-1R Inhibitor, Axatilimab, for Prevention of Acute and Chronic GVHD After HLA-Matched Related and Unrelated Donor Allogeneic Stem Cell Transplantation

NCT07808112
View directory record Official record
Conditions
Graft -Versus-host-disease
Interventions
Hematopoietic Cell Transplantation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil (MMF), Axatilimab
Procedure · Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 30, 2026, 2:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Reslizumab (3.0 mg/kg) in the Reduction of Clinical Asthma Exacerbations in Patients (12-75 Years of Age) With Eosinophilic Asthma

NCT01287039
View directory record Official record
Conditions
Eosinophilic Asthma
Interventions
Reslizumab, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
12 Years to 75 Years
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
26
States / cities
Scottsdale, Arizona • Los Angeles, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 30, 2026, 2:31 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Eosinophilic Asthma

NCT05748600
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma Attack
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
146
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 123 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 2:31 AM EDT